Akorn Inc. received a warning letter from the U.S. Food and Drug Administration following an inspection of the generic drugmaker’s Decatur, Illinois manufacturing plant during 2018.
GlaxoSmithKline Plc will actively look to buy early-stage assets and partner with companies, the drugmaker’s chief executive officer said.
Bristol-Myers Squibb Co. will buy Celgene Corp. for about $74 billion, creating one of the largest pharmaceutical companies and combining two significant cancer medicine businesses.
Akorn Inc. said the company’s chief executive officer would retire following the drugmaker’s inability to salvage a takeover deal with Germany’s Fresenius SE.
Pharmacy chain CVS Health Corp. won U.S. antitrust approval for the $69 billion acquisition of health insurer Aetna Inc., the Justice Department said.
German company Bayer AG is laying off 227 staffers at the company’s manufacturing plant in Berkeley, California. Most of the cuts took place on October 3, 2018.
Pfizer announced the company’s succession plan for when Ian Read steps down as chief executive officer on January 1, 2019.
Walgreens Boots Alliance Inc. will pay $34.5 million to settle charges that the company misled investors about the increased risk of missing a key financial goal related to its merger in 2012, the top U.S. securities regulator said.
Realm Therapeutics Slashes Staff and Explores Potential Sale as the Company Conducts a Strategic Review
Realm Therapeutics opted to discontinue all drug development programs and is considering a potential sale of the Malvern, Pa.-based company following a clinical trial failure with the atopic dermatitis treatment PR022.
Takeda Pharmaceutical will shutter the company’s Deerfield, Ill., U.S. headquarters and move the operations to Boston as the company consolidates operations following the $62 billion acquisition of Shire. The Illinois facility employs about 1,000 people.